Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 16;60(12):2070.
doi: 10.3390/medicina60122070.

Prognostic Value of Immune Scoring System for Colorectal Cancer Patients with Peritoneal Metastasis

Berke Manoğlu  1 , Selman Sökmen  1 , Tufan Egeli  1 , Zekai Serhan Derici  1 , Cihan Ağalar  1 , Süleyman Özkan Aksoy  1
Affiliations

Prognostic Value of Immune Scoring System for Colorectal Cancer Patients with Peritoneal Metastasis

Berke Manoğlu et al. Medicina (Kaunas). .

Abstract

Background and Objectives: There is no reliable immune scoring system that can help us predict the postoperative outcomes of colorectal cancer patients with peritoneal metastases after cytoreductive surgery. In this cohort, the aims were (1) to evaluate the postoperative morbidity, mortality and surgical oncological outcomes in colorectal cancer patients with peritoneal metastasis; (2) to compare oncological and postoperative outcomes of colon cancer patients with peritoneal metastasis and rectal cancer patients with peritoneal metastasis; and (3) to assess the prognostic value of the modified Glasgow Prognostic Score (mGPS) and the CRP-albumin ratio (CAR). Materials and Methods: A prospectively maintained database of 258 patients who underwent cytoreductive surgery for peritoneal metastases of colorectal origin between 2007 and 2024 was analyzed. According to the anatomical location of the primary tumor, two different groups were created: rectum cancer patients with peritoneal metastasis (Group A) and colon cancer patients with peritoneal metastasis (Group B). All standard clinico-pathological characteristics, operative findings, morbi-mortality results, and final oncologic outcomes were compared between Groups A and B. We evaluated whether CAR and mGPS could predict postoperative morbi-mortality and overall survival in the two groups or not. Results: No significant difference was detected between Groups A and B in terms of clinical-demographic characteristics. In both groups, the preoperative mGPS and CAR values were statistically significantly higher in those who developed postoperative high-grade complications (C-D grade III/IV) (p < 0.001) and those who died perioperatively (p = 0.001 and p = 0.002). Conclusions: In multivariate Cox analysis, the CAR was found to be an independent prognostic factor for overall survival in this cohort. CAR and mGPS predicted high-grade complications and postoperative mortality in both groups.

Keywords: CAR; colorectal cancer; immunoscore; mGPS; peritoneal metastases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Overall survival results between Group A and Group B patients. [Log Rank (Mantel–Cox) p = 0.002, chi-square].
See this image and copyright information in PMC

References

    1. World Health Organization GLOBOCAN Database. 2021. [(accessed on 8 March 2021)]. Available online: https://gco.iarc.fr/today/home.
    1. Gelli M., Huguenin J.F.L., de Baere T., Benhaim L., Marianai A., Boige V., Malka D., Sourouille I., Ducreux M., Elias D., et al. Peritoneal and extraperitoneal relapse after previous curative treatment ofperitoneal metastases from colorectal cancer: What survival can we expect? Eur. J. Cancer. 2018;100:94–103. doi: 10.1016/j.ejca.2018.04.015. - DOI - PubMed
    1. Lurvink R.J., Bakkers C., Rijken A., van Erning F.N., Nienhuijs S.W., Burger J.W., Creemers G.J., Verhoef C., Lemmens V.E., De Hingh I.H. Increase in the incidence of synchronous metachronous peritoneal metastases in patients with colorectal cancer: A nationwide study. Eur. J. Surg. Oncol. 2021;4:1026–1033. doi: 10.1016/j.ejso.2020.11.135. - DOI - PubMed
    1. Franko J., Shi Q., Meyers J.P., Maughan T.S., Adams R.A., Seymour M.T., Creemers G.J., Verhoef C., Lemmens V.E., De Hingh I.H. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancer of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–1719. doi: 10.1016/S1470-2045(16)30500-9. - DOI - PubMed
    1. Sanchez-Hidalgo J.M., Rodriguez-Ortiz L., Arjona-Sanchez A., Rufian-Pena S., Casado-Adam A., Cosano-Alvarez A., Briceño-Delgado J. Colorectal peritoneal metastases: Optimal management review. World J. Gastroenterol. 2019;25:3484–3502. doi: 10.3748/wjg.v25.i27.3484. - DOI - PMC - PubMed

Substances